Adult Stem Cell Assay Market : Segmentation, Industry Trends and Development to 2025 – Scientect

The report is an all-inclusive research study of the global Adult Stem Cell Assay market taking into account the growth factors, recent trends, developments, opportunities, and competitive landscape. The market analysts and researchers have done extensive analysis of the global Adult Stem Cell Assay market with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided accurate and reliable market data and useful recommendations with an aim to help the players gain an insight into the overall present and future market scenario. The Adult Stem Cell Assay report comprises in-depth study of the potential segments including product type, application, and end user and their contribution to the overall market size.

The Adult Stem Cell Assay Market carries out financial changes that occur year by years in market, with information about upcoming opportunities and risk to keeps you ahead of competitors. The report also describes top company profiles that present in market with trends worldwide. This research guided you for extending business.

The Adult Stem Cell Assay Market research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data and statistically-supported and industry-validated market data and projections with a suitable set of assumptions and methodology. It provides analysis and information by categories such as market segments, regions, and product type and distribution channels.

For more insights into the Market, request a sample of this report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2728130&source=atm

segment by Type, the product can be split into Viability/Cytotoxicity Isolation & Purification Cell Identification Proliferation Differentiation Function Apoptosis Market segment by Application, split into Regenerative Medicine & Therapy Development Drug Discovery & Development Clinical Research

Market segment by Regions/Countries, this report covers North America Europe China Japan Southeast Asia India Central & South America

A proper understanding of the Adult Stem Cell Assay Market dynamics and their inter-relations helps in gauging the performance of the industry. The growth and revenue patterns can be revised and new strategic decisions taken by companies to avoid obstacles and roadblocks. It could also help in changing the patterns using which the market will generate revenues. The analysis includes an assessment of the production chain, supply chain, end user preferences, associated industries, proper availability of resources, and other indexes to help boost revenues.

For Information On The Research Approach Used In The Report, Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2728130&source=atm

Market Segmentation based On Type, Application and Region:

The global Adult Stem Cell Assay is analyzed for different segments to arrive at an insightful analysis. Such segmentation has been done based on type, application and Region.

Global Adult Stem Cell Assay market is presented to the readers as a holistic snapshot of the competitive landscape within the given forecast period. It presents a comparative detailed analysis of the all regional and player segments, offering readers a better knowledge of where areas in which they can place their existing resources and gauging the priority of a particular region in order to boost their standing in the global market.

The Global Adult Stem Cell Assay Market is gaining pace and businesses have started understanding the benefits of analytics in the present day highly dynamic business environment. The market has witnessed several important developments over the past few years, with mounting volumes of business data and the shift from traditional data analysis platforms to self-service business analytics being some of the most prominent ones.

For the future period, sound forecasts on market value and volume are offered for each type and application. In the same period, the report also provides a detailed analysis of market value and consumption for each region. These insights are helpful in devising strategies for the future and take necessary steps. New project investment feasibility analysis and SWOT analysis are offered along with insights on industry barriers. Research findings and conclusions are mentioned at the end.

Reasons for Buying This Report:

It Provides A Forward-Looking Perspective on Different Factors Driving or Restraining Market Growth.

It Provides A Five-Year Forecast Assessed on The Basis of How the Market Is Predicted to Grow

It Helps in Understanding the Key Product Segments and Their Future.

It Provides Pin Point Analysis of Changing Competition Dynamics and Keeps You Ahead of Competitors.

It Helps in Making Informed Business Decisions by Having Complete Insights of Market and By Making an In-Depth Analysis of Market Segments.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2728130&licType=S&source=atm

Table of Content:

For More Information Kindly Contact:

ResearchMoz

Mr. Rohit Bhisey,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

Follow this link:
Adult Stem Cell Assay Market : Segmentation, Industry Trends and Development to 2025 - Scientect

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Comprehensive Study Explores Huge Growth In Future – Scientect

Autologous Stem Cell and Non-Stem Cell Based Therapies Marketis a professional and in-depth market report that focuses on primary and secondary drivers, market share, possible sales volume, leading segments and geographical analysis of the Chemical and Materials industry. It shows that the rise in market value is generally attributed to the rising growth of the application industries and the subsequent rise in demand for applications. TheAutologous Stem Cell and Non-Stem Cell Based Therapies Marketanalysis gives an examination of various segments that are relied upon to witness the quickest growth amid the approximate forecast frame. The competitive landscape section of the Autologous Stem Cell and Non-Stem Cell Based Therapies Marketreport brings into light a clear insight about the market share analysis of major industry players.

Europe autologous stem cell and non-stem cell based therapies market is registering a substantial CAGR in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. The rise in the market can be attributed growing awareness of the therapeutic potential of stem cells in effective disease management and increased public-private investment in the development of stem cell therapies.

Get Free Sample Report + All Related Graphs & Charts: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Prominent Key Players Covered in the report:

Takeda Pharmaceutical Company Limited, Cytori Therapeutics Inc., General Electric Spiegelberg GmbH & Co. KG ., Medtronic, Natus Medical Incorporated., Integra LifeSciences Corporation, RAUMEDIC AG, Abbott., Endotronix, Inc. among others.

Autologous Stem Cell and Non-Stem Cell Based Therapies market is framed with a bunch of Graphical Statistics, Table and Figures, Data Analysis Representation described in detail with a transparent goal to target potential company stakeholders. Featuring Industry Chain Structure strongly gives out the overview of market growth and it becomes easy to project the hurdles and upsurge profit graphs.

Coming to the Competitive landscape this Autologous Stem Cell and Non-Stem Cell Based Therapies market report gives out each and every aspect required to measure the existing market performance including technological advancements, business overview, positive and negative factors of market position and challenges faced but the market leaders to rank themselves above all. Quality parameters like Autologous Stem Cell and Non-Stem Cell Based Therapies sales reach, regional coverage, production price trends, and manufacturing cost structure are also studied to give out perfect competition outlook

Major Regions as Follows:

How Does This Market Insights Help?

Key Pointers Covered in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Prime Factors Influencing Market Growth

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Overview:

Later, the report focuses on regions operational coverage across the world mainly sales (K Units), revenue (Million USD), market share and growth rate variable within each region depending upon its capacity. This research also results to measure global Autologous Stem Cell and Non-Stem Cell Based Therapies competitors according to specific regions for development and compound growth rate.

Reasons to Purchase this Report

Significant Market Features:

This report features a mainly top to bottom approach to target key aspects of Autologous Stem Cell and Non-Stem Cell Based Therapies market that includes, Gross Revenue, CAGR, Key Players, Cost Structure, Production Capacity, Sales Analysis and Future Growth Trends projected on the basis of historical Autologous Stem Cell and Non-Stem Cell Based Therapies research.

TABLE OF CONTENTS

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers and Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

In conclusion, the Autologous Stem Cell and Non-Stem Cell Based Therapies Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

Get Enquiry About This Comprehensive Report: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market&utm_source=&kunal

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia.

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rates

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Continued here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Comprehensive Study Explores Huge Growth In Future - Scientect

Global Allogeneic Stem Cells Market shows Promising Growth Rates with CAGR of 10.19%, Future Analysis and its Trends – Scientect

Global Allogeneic Stem Cells Market is expected to grow at a CAGR of 10.19% from 2020 to 2023 and Allogeneic Stem Cells Market report explains why and how it is going to achieve this growth. It provides vital information on every parameter which is required for making strategic decisions and development of every business in Allogeneic Stem Cells industry. It would come handy to understand market situations, top competitors with their focused segments, regions etc.

Request a Sample Copy of the Report For COVID-19 Impact Analysis onAllogeneic Stem Cells Market

The latest trend gaining momentum in the market is the special drug designations.

According to the report, one of the major drivers for this market is the new product approvals.

Further, the report states that one of the major factors hindering the growth of this market is the stringent regulations.

Global Allogeneic Stem Cells Market: About this market

Allogeneic stem cells market analysis considers sales from regenerative therapy and drug discovery and development applications. Our study also finds the sales of allogeneic stem cells in Asia, Europe, North America, and ROW. In 2020, the regenerative therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as functional restoration of tissues will play a significant role in the regenerative therapy segment to maintain its market position. Also, our global allogeneic stem cells market report looks at factors such as new product approvals, increasing strategic alliances in the field of regenerative medicines, and investments in the field of regenerative medicines. However, stringent regulations, high cost of allogeneic stem cell therapies, and serious complications associated with stem cell therapies may hamper the growth of the allogeneic stem cell industry over the forecast period.

TheTop Manufacturers/playersincluding:-

Biosolution Co. Ltd., Cynata Therapeutics Ltd., JCR Pharmaceuticals Co. Ltd., Lineage Cell Therapeutics Inc., MEDIPOST Co. Ltd., MiMedx Group Inc., Osiris Therapeutics Inc., Stempeutics Research Pvt. Ltd., and Takeda Pharmaceutical Co. Ltd.

Get a Sample PDF of report https://www.360marketupdates.com/enquiry/request-sample/14829360

Market Segment of Allogeneic Stem Cells Industry:

Global Allogeneic Stem Cells Market: Overview

Competitive Landscape

Feel Free to Ask Question Before Purchasing the Report at https://www.360marketupdates.com/enquiry/pre-order-enquiry/14829360

Allogeneic Stem Cells Market Report provides comprehensive analysis of-

Key Summary of Allogeneic Stem Cells Market Growth Report:

In our market size and forecast determination efforts, in-depth secondary research was initially completed to realize an honest perspective of the market in each region. Extensive primary research was also administered by interviewing key executives from the industry. These interviews helped us to fill-in the info gaps after secondary research. Several secondary sources like encyclopedia, directories, and databases are wont to identify and collect information useful for this extensive techno-commercial study.

Key Questions Answered in ROY Allogeneic Stem Cells Market Report:

Purchase this report (Price2500 USD for a single-user license)@ https://www.360marketupdates.com/purchase/14829360

In the end, the Allogeneic Stem Cells Market report makes some important proposals for a new project of the Allogeneic Stem Cells Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of Global Allogeneic Stem Cells Industry covering all important parameters.

Table of Contents included in Allogeneic Stem Cells Market ROY Report

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market landscape

PART 06: Market segmentation by end-user industry

PART 07: Market segmentation by application

PART 08: Geographical Segmentation

PART 09: A Decision framework

PART 10: Impact of drivers and challengesAnd Many More Parts Covered.

Be sure to follow on Linkedin at @360 Market Updatesfor more on growth research and the research market.

CONTACT US

Name: Mr. Ajay More

Email: [emailprotected]

Organization: 360 Market Updates

Phone: +1 424 253 0807 / + 44 203 239 8187

OUR OTHER REPORTS:

Chemicals Pump Market 2020 Global Industry Growth Rate, Share, Size, Price, Prospect, Developments and Forecast till 2026

Global Gynecological Cancer Drugs Market 2020 Indepth Analysis of Current Market Trends including Industry Share, Size, Manufacturers and Future Prospects

Social Gaming Market 2020 Impact of Covid 19 on Industry Share, Size, Price, CAGR, Growth Rate and Future Prospects

Global Food Composter Machines Market 2020 Industry Growth Factor, Top Manufacturers and Indepth Study of Market Share, Size, Price and Developments

Global Flat-Panel TV IC Market 2020 Industry Growth Factor, Top Manufacturers and Indepth Study of Market Share, Size, Price and Developments

See the rest here:
Global Allogeneic Stem Cells Market shows Promising Growth Rates with CAGR of 10.19%, Future Analysis and its Trends - Scientect

Method regrows cartilage to cushion bones – Futurity: Research News

Share this Article

You are free to share this article under the Attribution 4.0 International license.

Researchers have found a way, in mice and human tissue, to regenerate the cartilage that eases movement between bones.

Loss of this slippery and shock-absorbing tissue layer, called articular cartilage, is responsible for many cases of joint pain and arthritis, which afflicts more than 55 million Americans.

The researchers can envision a time when people are able to avoid getting arthritis in the first place by rejuvenating their cartilage before it is badly degraded.

Nearly 1 in 4 adult Americans suffer from arthritis, and far more are burdened by joint pain and inflammation generally.

The researchers figured out how to regrow articular cartilage by first causing slight injury to the joint tissue, then using chemical signals to steer the growth of skeletal stem cells as the injuries heal.

Cartilage has practically zero regenerative potential in adulthood, so once its injured or gone, what we can do for patients has been very limited, says co-senior author Charles K.F. Chan, assistant professor of surgery at Stanford Universitys School of Medicine.

Its extremely gratifying to find a way to help the body regrow this important tissue, Chan says.

The work builds on previous research that resulted in isolation of the skeletal stem cell, a self-renewing cell that is also responsible for the production of bone, cartilage and a special type of cell that helps blood cells develop in bone marrow.

Articular cartilage is a complex and specialized tissue that provides a slick and bouncy cushion between bones at the joints. When this cartilage is damaged by trauma, disease, or simply thins with age, bones can rub directly against each other, causing pain and inflammation, which can eventually result in arthritis.

Damaged cartilage can be treated through a technique called microfracture, in which tiny holes are drilled in the surface of a joint. The microfracture technique prompts the body to create new tissue in the joint, but the new tissue is not much like cartilage.

I realized the only way to understand the process was to look at what stem cells are doing after microfracture.

Microfracture results in what is called fibrocartilage, which is really more like scar tissue than natural cartilage, says Chan. It covers the bone and is better than nothing, but it doesnt have the bounce and elasticity of natural cartilage, and it tends to degrade relatively quickly.

The most recent research arose, in part, through the work of surgeon and lead author Matthew Murphy, a visiting researcher at Stanford who is now at the University of Manchester.

I never felt anyone really understood how microfracture really worked, Murphy says. I realized the only way to understand the process was to look at what stem cells are doing after microfracture.

For a long time, Chan says, people assumed that adult cartilage did not regenerate after injury because the tissue did not have many skeletal stem cells that could be activated. Working in a mouse model, the team documented that microfracture did activate skeletal stem cells. Left to their own devices, however, those activated skeletal stem cells regenerated fibrocartilage in the joint.

But what if the healing process after microfracture could be steered toward development of cartilage and away from fibrocartilage?

The researchers knew that as bone develops, cells must first go through a cartilage stage before turning into bone. They had the idea that they might encourage the skeletal stem cells in the joint to start along a path toward becoming bone, but stop the process at the cartilage stage.

The researchers used a powerful molecule called bone morphogenetic protein 2 (BMP2) to initiate bone formation after microfracture, but then stopped the process midway with a molecule that blocked another signaling molecule important in bone formation, called vascular endothelial growth factor (VEGF).

What we ended up with was cartilage that is made of the same sort of cells as natural cartilage with comparable mechanical properties, unlike the fibrocartilage that we usually get, Chan says. It also restored mobility to osteoarthritic mice and significantly reduced their pain.

As a proof of principle that this might also work in humans, the researchers transferred human tissue into mice that were bred to not reject the tissue, and were able to show that human skeletal stem cells could be steered toward bone development but stopped at the cartilage stage.

The next stage of research is to conduct similar experiments in larger animals before starting human clinical trials. Murphy points out that because of the difficulty in working with very small mouse joints, there might be some improvements to the system they could make as they move into relatively larger joints.

The first human clinical trials might be for people who have arthritis in their fingers and toes. We might start with small joints, and if that works we would move up to larger joints like knees, Murphy says.

Right now, one of the most common surgeries for arthritis in the fingers is to have the bone at the base of the thumb taken out. In such cases we might try this to save the joint, and if it doesnt work we just take out the bone as we would have anyway. Theres a big potential for improvement, and the downside is that we would be back to where we were before.

One advantage of their discovery is that the main components of a potential therapy are approved as safe and effective by the FDA, says co-senior author Michael Longaker, professor of surgery.

BMP2 has already been approved for helping bone heal, and VEGF inhibitors are already used as anti-cancer therapies, he says. This would help speed the approval of any therapy we develop.

Joint replacement surgery has revolutionized how doctors treat arthritis and is very common: By age 80, 1 in 10 people will have a hip replacement and 1 in 20 will have a knee replaced. But such joint replacement is extremely invasive, has a limited lifespan and is performed only after arthritis hits and patients endure lasting pain.

The researchers say they can envision a time when people are able to avoid getting arthritis in the first place by rejuvenating their cartilage in their joints before it is badly degraded.

One idea is to follow a Jiffy Lube model of cartilage replenishment, Longaker says. You dont wait for damage to accumulateyou go in periodically and use this technique to boost your articular cartilage before you have a problem.

The work appears in the journal Nature Medicine.

Support for the research came from the National Institutes of Health, the California Institute for Regenerative Medicine, the Oak Foundation, the Pitch Johnson Fund, the Gunn/Olivier Research Fund, the Stinehart/Reed Foundation, The Siebel Foundation, the Howard Hughes Medical Institute, the German Research Foundation, the PSRF National Endowment, National Center for Research Resources, the Prostate Cancer Research Foundation, the American Federation of Aging Research, and the Arthritis National Research Foundation.

Source: Stanford University

See more here:
Method regrows cartilage to cushion bones - Futurity: Research News

Pro-life groups applaud Trump administration advisory board for rejecting fetal tissue research proposals – Christianity Daily

(Photo : National Institutes of Health) Health and Human Services Secretary Alex Azar speaks at the NIH campus on March 20, 2018.

Numerous influential pro-life groups have come out in strong support of a decision by a federal ethics board to reject 13 out of 14 applications for fetal tissue research funding, including both grants and contracts.

Groups such as the National Right to Life, U.S bishops pro-life committee, and Susan B. Anthony List have lauded the Trump administration for the overwhelming decision of the ethics board. Mallory Quigby of the Susan B. Anthony List described the board's decision-making process as "a serious review of the ethical considerations surrounding use of human fetal tissue in research."

The board was created by the Trump administration in 2019 to review applications for funding of fetal tissue research conducted outside of NIH facilities. In addition, the ChristianPost reported last year that HHS imposed a moratorium on all new fetal tissue research at NIH facilities. This is in addition to a $20 million research program from 2018 focused on alternative experimental models to human fetal tissue.

The advisory board considered ethical questions as required by the law constituting the board.

According to Science, "At least 10 of the board's 15 members have publicly opposed abortion, fetal tissue research, human embryonic stem cell research, contraception, or a combination of." Lawrence Goldstein, a neuroscientist at the University of California, San Diego, has been the only board member to come out strongly in favor of fetal tissue research. He told ScienceInsider that "excellent disease-relevant research will likely not be funded and it will not be possible to reduce the need for human fetal tissue in disease research." Currently, human fetal tissue from abortions is used for research on diseases like HIV and Alzheimer's and as testing cells for multiple candidate coronavirus vaccines.

The one acceptance out of 14 proposals, by a 9-to-6 vote, was a proposal to develop an alternative to fetal tissue which used existing fetal tissue stored in a biorepository as a comparator. Current NIH guidelines for research require a fetal tissue comparator, described as the gold standard, for any research on human fetal tissue replacements and alternatives.

Alex Azar, the HHS secretary, will make the final decision about whether to fund each proposal.

Read more here:
Pro-life groups applaud Trump administration advisory board for rejecting fetal tissue research proposals - Christianity Daily

Herbert Irving Comprehensive Cancer Center Earns National Cancer Institute Renewal – Newswise

Newswise NEW YORK, NYThe Herbert Irving Comprehensive Cancer Center (HICCC) at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian Hospital (CUIMC campus) has been competitively renewed as a designated Comprehensive Cancer Center by the federal governments National Cancer Institute (NCI), the largest funder of cancer research in the world.Originally funded in 1972, the HICCC gained comprehensive status in 1979. The most recent renewal marks more than 40 years since the HICCC has maintained its status as a comprehensive cancer center.

NCI-designated Comprehensive Cancer Centers must meet rigorous standards for patient-centered and laboratory research that bridges scientific disciplines and is focused on developing better approaches to preventing, diagnosing, and treating cancer.

After a thorough evaluation of every facet of HICCCs operations, the NCI awarded the HICCC with the Comprehensive Cancer Center designation, the highest ranking given. The redesignation comes with a five-year support grant of $26.5 million, an increase of nearly 40% in funding over the previous support grant.

The funding supports extensive programs at the HICCC that affect cancer research, patient care, education/training and community outreach, including:

For patients coming to HICCC, that means their care is informed by the most sophisticated, cutting-edge, evidence-based methods of preventing, diagnosing, and treating cancer.

As a comprehensive cancer center housed in one of the nations most prestigious hospitals and academic medical research centers, we offer our patients the most compassionate, cutting-edge care available, from top scientists and clinicians, says Anil K. Rustgi, MD, director of the Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center and NewYork-Presbyterian and interim dean of Columbias Faculties of Health Sciences and Medicine.Having access to this robust cancer care and research ecosystem is crucial for the patients we serve in Upper Manhattan and the New York City metropolitan area, where the incidence of some common cancers is higher than the national average.

The Herbert Irving Comprehensive Cancer Center has demonstrated that it is truly one of the nations preeminent centers for cancer care, research, patient education, and advocacy, says Steven J. Corwin, MD, president and CEO of NewYork-Presbyterian. We are proud to receive this recognition and support from the National Cancer Institute, which will allow us to continue the critical work of pioneering research and advancing cancer care for patients and families in our local community, nation, and around the world.

Accelerating Research to Improve Cancer Care

The HICCC was one of the first cancer centers to be funded by the NCI Cancer Center program. It is one of 51 NCI-designated Comprehensive Cancer Centers in the United States and one of three in New York City.

Research in the HICCC has led to widespread advances in cancer research and progress in cancer care, including new immunotherapy approaches in lung and prostate cancer, the first effective treatment for connective tissue cancers, and new surgical protocols for treating uterine and cervical cancer.

HICCC oncologists also help guide the testing of new therapies in nationwide clinical trials through their leadership positions in the NCIs National Clinical Trials Network, the NCI Community Oncology Research Program (NCORP), SWOG Cancer Research Network, and other clinical trial collaboratives.

Over the past five years, researchers at HICCC have made new discoveries in cancer immunotherapy, expanded the use of systems biology and genomics to identify personalized cancer treatments, and introduced mathematical and engineering approaches to the study of cancer.

Increasing Access to Care

HICCC physicians delivered more than 120,000 cancer treatments last year, up from 90,000 in 2014. The number of patients enrolled in clinical trials at the center has increased over the past five years by nearly 40%, with underrepresented minorities accounting for nearly 50% of all study participants.

HICCC is committed to providing underserved patients with the best cancer care. More than 60% of the cancer centers patients are non-white, 35% are immigrants, and many live in poverty. The cancer center was one of the first to join the NCI Community Oncology Research Program, which helps bring the latest cancer treatments to underserved patients within their own communities. The center also has expanded its Community Outreach and Engagement initiative, establishing a formal office that integrates the centers research efforts with community needs and priorities and guided by inclusive Community Advisory and Patient Advocacy Boards to identify and address additional barriers to cancer care in the community.

Over the past five years, the HICCC has made key leadership appointments in radiation oncology, immunotherapy, precision oncology, computational biology, and stem cell research.

Im proud to support the Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center and NewYork-Presbyterian and their cutting-edge cancer research and patient care,said U.S. Senator Charles Schumer. HICCC has earned redesignation as a Comprehensive Cancer Center by the National Cancer Institute and will be awarded increased federal funding to support their critical work in cancer care, research and patient education and advocacy. I will continue to advocate on behalf of this prestigious hospital and academic research center and the talented medical professionals who valiantly care for New Yorkers, lead the world in advancing medical research, and educate our communities day in and day out.

As one of the nations leadingcenters forcancercare, theHerbert Irving ComprehensiveCancerCenterat Columbia UniversityIrving MedicalCenterandNewYork-Presbyterian has been at the forefront ofcancerresearch, patient care and education, advocacy, and more,saidU.S. Senator Kirsten Gillibrand.This redesignation confirms thatHICCC is a leader in groundbreakingcancerresearch. I am thankful that this top-notch institution will continue its important work on behalf of New Yorkers andindividuals across the nation fightingcancer.

After months of efforts to combat the spread of the coronavirus, we see more clearly than ever the importance of a resilient, multidisciplinary, and interconnected public health infrastructure and clinical research network in our community and around the nation,said Representative Adriano Espaillat (NY-13). As a National Cancer Institute-designated Center, the Herbert Irving Comprehensive Cancer Center, in collaboration with research and treatment centers across the country, has been at the forefront of groundbreaking progress in cancer research and treatment. This is a tremendous honor that recognizes the hard work and dedication to the highest quality of care that NewYork-Presbyterian/Columbia University Irving Medical Center strives for and delivers to the Washington Heights and Northern Manhattan community.

Notable accomplishments in past five years

####

The Herbert Irving Comprehensive Cancer Center (HICCC)of Columbia University and NewYork-Presbyterian Hospital (CUIMC campus) is dedicated to curing cancer through innovative basic, clinical, and population-based research and outstanding patient care. HICCC researchers and physicians are dedicated to understanding the biology of cancer and to applying that knowledge to the design of cancer therapies and prevention strategies that reduce its incidence and progression and improve the quality of life for those affected by cancer. With expertise in harnessing translational research to bridge scientific discovery to clinical applications, the HICCCs goal is to provide novel diagnostic, therapeutic, and preventive approaches and education to cancer for patients and community members in the New York City area, New York State, the United States, and the world. For more information, visit cancer.columbia.edu.

Columbia University Irving Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the Vagelos College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Irving Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cuimc.columbia.edu or columbiadoctors.org.

NewYork-Presbyterian NewYork-Presbyterian is one of the nations most comprehensive, integrated academic health care systems, encompassing 10 hospital campuses across the Greater New York area, more than 200 primary and specialty care clinics and medical groups, and an array of telemedicine services.

A leader in medical education, NewYork-Presbyterian Hospital is the only academic medical center in the nation affiliated with two world-class medical schools, Weill Cornell Medicine and Columbia University Vagelos College of Physicians and Surgeons. This collaboration means patients have access to the countrys leading physicians, the full range of medical specialties, latest innovations in care, and research that is developing cures and saving lives.

Ranked the #4 hospital in the nation and #1 in New York in U.S. News & World Reports Best Hospitals rankings, NewYork-Presbyterian Hospital is also recognized as among the best in the nation in the U.S. News Best Childrens Hospitals rankings. Founded nearly 250 years ago, NewYork-Presbyterian Hospital has a long legacy of medical breakthroughs and innovation, from the invention of the Pap test to pioneering the groundbreaking heart valve replacement procedure called TAVR.

NewYork-Presbyterians 47,000 employees and affiliated physicians are dedicated to providing the highest quality, most compassionate care to New Yorkers and patients from across the country and around the world.

For more information, visit http://www.nyp.org and find us on Facebook, Twitter, Instagram, and YouTube.

Here is the original post:
Herbert Irving Comprehensive Cancer Center Earns National Cancer Institute Renewal - Newswise

GoBroad Healthcare Group Showcases Innovative Hematologic Treatment Capabilities at the China Precision Medicine Forum – PRNewswire

40 experts delivered keynote speeches or participated in discussions during the online event, which attracted participants from more than 300 hospitals/institutes and over 40,000 views. Prof. John Gribben, Centre Lead of Haemato-Oncology at Barts Cancer Institute at Queen Mary, University of London, UK and the President of the European Hematology Association (EHA), gave a speech on Advances in Diagnosis and Treatment of Lymphoma in Europe; Prof. Dong Chen, Division of Hematopathology, Department of Laboratory Medicine and Pathology at Mayo Clinic, presented his insights on Integrated Hematopathology Reporting; Prof. Jun Zhu, Director of the Department of Internal Medicine at Beijing Cancer Hospital, who is also the Vice Chairman of GoBroad's Scientific Advisory Board, shares the Current Status and Prospects of the Lymphoma-related Investigational New Drug (IND) in China, etc.

Driven by strong innovation in both research and operation, GoBroad Healthcare Group has created a unique model for specialized treatments in hospitals since its inception in 2017.As of the end of July this year, the healthcare group has conducted over 600 cases of hematopoietic stem cell transplant, registered around 30 clinical trials of Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and undertaken over 1,000 CAR-T treatments. The healthcare group has also published eight academic papers in key hematology journals, includingBloodandLeukemia.

GoBroad Healthcare Group offers advanced services and treatments for the entire range of specialties in hematologic malignancies. Its clinical programs include the discovery and treatment of lymphoma and leukemia in adults and children and a centre dedicated to hematologic and respiratory diseases. GoBroad Medical Institute of Hematology (Beijing Centre) has successfully undertook cutting-edge treatments such as a 23-second allogeneic hematopoietic cell transplant with a survival rate of 88.7%, higher than the global average. GoBroad Medical Institute of Hematology (Guangdong Centre) has adopted the TCR-T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant to largely reduce GVHD and increase the survival rate. For the first case around the world, the team successfully conducted hematopoietic cell transplant to treat a young patient suffering from Lysinuric Protein Intolerance (LPI) and Systemic Lupus Erythematosus (SLE).

"At the very beginning, we saw which clinical services were in urgent need. Innovation has propelled GoBroad Healthcare Group to new heights, attracting top talent around the world," said the Mr. Zhang, CEO of GoBroad. "As we develop our own competencies in research and clinical treatment in hematologic malignancies, we'd like to work with industry-leading experts and professionals across the globe to further develop our capabilities."

Powered by the expertise of Mayo Clinic and led by the Chief Physician at the Pathobiology Department of Peking University Health Science Center, GoBroad Healthcare Group has built a laboratory for integrated diagnostics to facilitate data-driven clinical decision-making and enhancement of patient services.

GoBroad values talent. At GoBroad Healthcare Group, experts can work on their research and clinical treatments freely, without administrative requirements. They also can work alongside a digitalized operations system; the healthcare group even rolled out digital products created for the specific clinical needs of healthcare professionals. In addition to attracting talent, GoBroad has also been committed to talent nurturing. Since the first day, the healthcare group has been partnering with top academic institutions such as Tongji University, Beijing University of Chinese Medicine and the Institute of Hematology & Blood Diseases Hospital at Tianjin in a range of educational programs.

About China Cancer Immunotherapy and Targeting Therapy Conference & GoBroad Annual Medical Conference

First launched in 2019, the event was joined by over 500 prominent medical experts across the globe to present the latest development, innovative insights in the field. Prof. Xiaodong Wang, member of the National Academy of Sciences, USA and director of China's National Institute Of Biological Sciences (NIBS), Prof. Mitchell S. Cairo of New York Medical College, Prof. J. Joseph Melenhorst of University of Pennsylvania and faculties from Mayo Clinic, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center and City of Hope National Medical Centre are invited to give keynote speeches.

About GoBroad Healthcare Group

Invested by Hillhouse Capital, GoBroad Healthcare Group is dedicated to creating a medical service and technological innovation platform integrating pharmaceutical production and research, with a focus on blood diseases and tumours, among other medical fields. Its medical ecosystem covers the entire hospital supply chain. From clinical laboratories, a medical imaging facility, and big data centres to biotherapy research and treatment. Currently, the group has three homoeopathy R&D centres and five hospitals in Beijing, Shanghai and Guangdong, with a total of 800 beds and 88 hematopoietic stem cell transplant wards.

SOURCE GoBroad Healthcare Group

Follow this link:
GoBroad Healthcare Group Showcases Innovative Hematologic Treatment Capabilities at the China Precision Medicine Forum - PRNewswire

Plant Stem Cell Market Research Study Including Growth Factors, Types And Application By Regions From 2020 To 2026 – StartupNG

CMI presents an in-depth overview of the GlobalPlant Stem Cell Market Study, detailing the latest product/industry coverage and market forecasts and status by 2027.Market research is categorized as a key area to accelerate marketization. The current market is evolving its presence and some of the major players in the study areOriflame Holding AG, MyChelle Dermaceuticals, LLC, Natura Therapeutics Inc, Aidan Products LLC, Mibelle Biochemistry, Phyto Science SDN BHD, and Renature Skin Care Inc.

This study focuses on the GlobalPlant Stem Cell market status, future forecast, growth opportunity, key market, and emerging players. The study objectives are to present thePlant Stem Cell growth in Key regions. In order to provide valuable insight by each key element of the market, the highest and slowest growing market segment in the study is described. Newmarket participants are emerging and are accelerating the transition in the antistatic market. Merger and acquisition activities are expected to change the market environment for this industry.

We Do Offer Sample of this report. Kindly go through the following information in order to access sample copy.

Note- This report sample includes:

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (Structure Of The Report)

Research methodology adopted by Coherent Market Insights

Get Sample Copy Of this Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/98

By Product Type: GlobalPlant Stem Cell Market, By Application.

Regional Markets:United States, Europe, China, Japan, Southeast Asia, India & Central & South America

List of Companies Mentioned:Oriflame Holding AG, MyChelle Dermaceuticals, LLC, Natura Therapeutics Inc, Aidan Products LLC, Mibelle Biochemistry, Phyto Science SDN BHD, and Renature Skin Care Inc.

1) Does Study provide Latest Impact on Market due to COVID & Slowdown?

Yes, the study has considered a chapter on Impact Analysis and this 2020 Edition of the report provides detailed analysis and its impact on growth trends and market sizing to better understand the current scenario.

2) How companies are selected or profiled in the report?

List of some players that are profiled in the report includes Oriflame Holding AG, MyChelle Dermaceuticals, LLC, Natura Therapeutics Inc, Aidan Products LLC, Mibelle Biochemistry, Phyto Science SDN BHD, and Renature Skin Care Inc.. the list is sorted to come up with a sample size of atleast 50 to 100 companies having greater topline value to get their segment revenue for market estimation.

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

3) Is it possible to narrow down business segments by Application of this study?

Yes, depending upon the data availability and feasibility check by our Research Analyst, a further breakdown in business segments by end-use application in relation to type can be provided (If applicable) by Revenue Size or Volume*.

4) What is the base year of the study? What time frame is covered in the report?

Furthermore, the years considered for the study are as follows:

Historical year 2014-2019

Base year 2019

Forecast period** 2020 to 2027 [** unless otherwise stated]

Get Free PDF Brochure Of this Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/98

** We will also include opportunities to utilize in micro markets that stakeholders can invest in, a detailed analysis of key competitors, and key services. **

GlobalPlant Stem Cell Market What to expect from this report:

Focused Study onNicheStrategy and Market Development & penetration Scenario

Top10 GlobalPlant Stem Cell Companies in Global Market Share Analysis:Leaders and Laggards in 2017, 2019

Gain strategic insights oncompetitor information to formulate effective R&D moves

Identify emerging players and createeffective counter-strategies to outpace competitive edge

Identify important and diverseproduct types/services offering carried by major players for market development

And many more .

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: GlobalPlant Stem Cell MARKET LANDSCAPE

Market Entropy Market segmentation analysis Market characteristics

PART 06: GlobalPlant Stem Cell MARKET SIZING

Market definition Market size and forecast Market sizing

PART 07: GlobalPlant Stem Cell MARKET SEGMENTATION

Segmentation Market opportunity Comparison

PART 08: CUSTOMER LANDSCAPE

PART 10: DECISION FRAMEWORK

PART 09: REGIONAL LANDSCAPE

PART 11: MARKET DYNAMICS: DRIVERS, TRENDS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

Apply Promo Code CMIFIRST1000 And Get Instant Discount Of USD 1000

To Purchase Report, Click Here https://www.coherentmarketinsights.com/insight/buy-now/98

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia.

**Be Safe and Stay Home**

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact:

Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Email:[emailprotected] United States of America: +1-206-701-6702 United Kingdom: +44-020-8133-4027 Japan: +050-5539-1737 India: +91-848-285-0837

Read more from the original source:
Plant Stem Cell Market Research Study Including Growth Factors, Types And Application By Regions From 2020 To 2026 - StartupNG

Stem Cell Market Trend 2020 Covid-19 Impact to Showing Impressive Growth by 2024 | Industry Trends, Share, Size, Top Key Players Analysis and…

Global Stem Cell Market Report 2020trend offers Complete examination of industry status and standpoint of significant areas dependent on of central participants, nations, item types, and end enterprises. This report focuses on the Stem Cell in Global market, especially inUnited States, Europe, China, Japan, South Korea, North America, India.Stem Cell Market report categorizes the market based on manufacturers, regions, type and application. Stem Cell Report 2020 (value and volume) by company, regions, product types, end industries, history data and estimate data.

Also, Report contains a comprehensive analysis of the important segments like market opportunities, import/export details, market dynamics, key manufacturers, growth rate, and key regions. Stem Cell Market report categorizes the market based on manufacturers, regions, type, and application. Stem Cell Market reports offer a detailed assessment of the Stem Cell including enabling technologies, current market situation, market assumptions, restraining factors.

Get a Sample PDF of Stem Cell Market 2020

List of Top Key-players in 2020 of Stem Cell Market:-

The Global Stem Cell market swot is provided for the international markets including progress trends, competitive landscape breakdown, and key in regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT REQUEST SAMPLE

The global stem cell market is expected to register a CAGR of 15% during the forecast period of 20182023. Stem cells are unspecialized cells, which have a remarkable property of developing into different kinds of cell types, during their early life and growth period inside the human body. When they divide, each cell has a potential to remain either the same or change into a specific cell type. Thus, under certain physiologic or experimental conditions, these cells can be induced to become tissue-specific or organ-specific with special functions.

Increased Awareness about Umbilical Stem Cells

Stem cells found in the umbilical cord blood are being used in treating a wide range of conditions (sickle cell disease, leukemia, multiple myeloma, lymphoproliferative disorders, SCID, Tay Sachs, etc.). Expecting couples are well aware that the birth of their child is the only chance to collect and store these valuable stem cells, which can be used to treat over 80 diseases. With over one million cord blood units in private storage, and continued support from the medical community and governments across the world, many researchers believe usage of umbilical cord cells for treatment will become a standard course. Currently, there is an increase in the number of clinical trials for testing future treatment possibilities of cord blood. Over 200 National Institutes of Health (NIH) funded clinical trials with cord blood are currently being conducted in the United States alone. In the United Kingdom, a petition has been submitted to increase the awareness of umbilical cord cells. In the United States, CordBloodAwareness.org was created out of a need to increase awareness about the life-saving power of umbilical cord blood stem cells. Through raising awareness, the hope is that more families will choose to donate so that ultimately more patients can be treated with umbilical cord blood stem cells, at the same time that research utilizing these cells progresses. This is driving the stem cell market. The other factors, such as the increase in the patient population, increase in the approval for clinical trials in stem cell research, growing demand for regenerative treatment option, and rising R&D initiatives to develop therapeutic options for chronic diseases are driving the stem cell market.

Ethical and Moral Framework

Stem cells are often viewed as an alternative form of therapy. However, there has been strong debate over the use of stem cells in the development of novel therapies. Stem cell banking raises ethical and also legal issues which highlight the need for a careful regulatory framework. Increasing tensions between public and private models of banking may require the adoption of an ethical framework. Many national and international regulatory firms have addressed these issues. For instance, in Europe, the European Group on the Ethics of Science and New Technologies stated that it should be freely done and the donor does not have any payment or reward. Such ethical and moral framework are hindering the growth of stem cell market. The other factors, such as expensive procedures and regulatory complications are also hindering the growth of the market.

United States Leads the Market in North America

In 2017, the United States stem cell market held the largest share in North America due to the presence of high-quality healthcare systems and modern medical technology in the country. Additionally, the growing importance of stem cell in public is likely to contribute towards the growth of the stem cell market.

Get a Sample PDF of Report @https://www.360marketupdates.com/enquiry/request-sample/12886257

The global Stem Cell market covers the vision of participant analysis by product types, market share, applications, sales, and revenue.

Highlighted points of Stem Cell Market Size:

Key Developments in the Stem Cell Market:

Inquire more and share questions if any before the purchase on this report@https://www.360marketupdates.com/enquiry/pre-order-enquiry/12886257

This Stem Cell Market Research/analysis Report Contains Answers to your following Questions

Reasons to Purchase the Report

Purchase this report (Price 4250 USD for a single-user license)@https://www.360marketupdates.com/purchase/12886257

Finally, the report Global Stem Cell Market 2020 describes the Stem Cell industry expansion game plan, the Stem Cell industry knowledge supply, appendix, analysis findings, and the conclusion.

About 360 Market Updates:

360 Market Updates is a credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Market Updates, our objective is to provide a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision-makers in finding the most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Info:

360 Market Updates

Mr. Ajay More

USA: +1 424 253 0807

UK: +44 203 239 8187

[emailprotected]

Allicin Market Size 2020 Industry Share, Size, Revenue, Latest Trends, Business Boosting Strategies, CAGR Status, Growth Opportunities and Forecast 2025 360 Market Updates

Allicin Market Size 2020 Industry Share, Size, Revenue, Latest Trends, Business Boosting Strategies, CAGR Status, Growth Opportunities and Forecast 2025 360 Market Updates

Ophthalmic Ultrasound System Market Size 2020 Research Reports, Industry Size, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis by 360 Market Updates

Canned Yellow Peach Market 2020 Industry Overview, Key Players Analysis, Emerging Opportunities, Comprehensive Research Study, Competitive Landscape and Potential of Industry from 2020-2026

Manual Homecare Bed Market Size 2020 Industry Size Analyzed by Business Opportunity, Development, Growth Factors, Applications Analysis and Future Prospects 2025

India Cake Market 2020 to Showing Impressive Growth by 2024 | Industry Trends, Share, Size, Top Key Players Analysis and Forecast Research By 360 Market Updates

See the original post here:
Stem Cell Market Trend 2020 Covid-19 Impact to Showing Impressive Growth by 2024 | Industry Trends, Share, Size, Top Key Players Analysis and...

Cytovia Therapeutics and NYSCF Announce Filing of Provisional Patent for iPSC-Derived NK Cells to Produce Unlimited On-Demand NK and CAR-NK Cells for…

NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeuticsan emerging biopharmaceutical company and the New York Stem Cell Foundation (NYSCF) Research institute today announced the filing of a provisional patent application with the U.S. Patent & Trademark Office (USPTO) for the differentiation of Natural Killer (NK) cells from induced pluripotent stem cells (iPSCs). The NYSCF Research Institute is a pioneer and acknowledged leader in stem cell technology, having developed the NYSCF Global Stem Cell Array, the premier automated robotic platform for reprogramming skin or blood into induced pluripotent stem cells (iPSCs) and differentiating them into disease-relevant cell types.

Cytovia and NYSCF are also collaborating on the process development of Good Manufacturing Practices (GMP) of iPSC NK and CAR-NK cells with the potential to file additional patents on the engineering, expansion and GMP manufacturing processes of iPSC NK cells to treat cancer.

Dr. Daniel Teper, CEO of Cytovia commented, This first patent application filing on iPSC-NK cells is an important milestone for Cytovia, positioning us as a pioneer in this emerging field. The use of iPSC-NK cells constitutes a transformational approach to cancer treatment, enabling the use of precision cell therapy for many patients. Cytovia plans to initiate first clinical trials with iPSC NK-cells in 2021.

Susan L Solomon, Chief Executive Officer of NYSCF added, We are delighted by the progress made by the NYSCF and Cytovia team in the differentiation and expansion of NK cells from an iPSC source. These iPSC-NK cells can be genetically modified to create iPSC-CAR-NK cells. In the coming months, the collaboration will focus on developing a standardized GMP process to support Cytovias iPSC-NK and iPSC-CAR NK therapeutic candidates for cancer.

ABOUT CAR NK CELL THERAPY Chimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR-NK cell therapy has demonstrated initial clinical relevance without the limitations of CAR-T, such as Cytokine Release Syndrome, neurotoxicity or Graft vs Host Disease (GVHD). Induced Pluripotent Stem Cells (iPSC) - derived CAR-NKs are naturally allogeneic, available off-the-shelf and may be able to be administered on an outpatient basis. Recent innovative developments with the iPSC, an innovative technology, allow large quantities of homogeneous genetically modified CAR NK cells to be produced from a master cell bank, and thus hold promise to expand access of cell therapy for many patients.

ABOUTTHE NEW YORK STEM CELL FOUNDATION RESEARCH INSTITUTE The New York Stem Cell Foundation (NYSCF) Research Institute is an independent non-profit organization accelerating cures and better treatments for patients through stem cell research. The NYSCF global community includes over 190 researchers at leading institutions worldwide, including the NYSCF Druckenmiller Fellows, the NYSCF Robertson Investigators, the NYSCF Robertson Stem Cell Prize Recipients, and NYSCF Research Institute scientists and engineers. The NYSCF Research Institute is an acknowledged world leader in stem cell research and in the development of pioneering stem cell technologies, including the NYSCF Global Stem Cell Array, which is used to create cell lines for laboratories around the globe. In 2019, NYSCF launched the Womens Reproductive Cancers Initiative, which aims to shift paradigms in the way these cancers are studied and treated, in collaboration with leading cancer experts across the globe. NYSCF focuses on translational research in an accelerator model designed to overcome barriers that slow discovery and replace silos with collaboration. For more information, visitwww.nyscf.org

ABOUT CYTOVIA THERAPEUTICS, INC Cytovia Therapeutics Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem, and CytoImmune Therapeutics. Learn more atwww.cytoviatx.com

For more information please contact:

View original post here:
Cytovia Therapeutics and NYSCF Announce Filing of Provisional Patent for iPSC-Derived NK Cells to Produce Unlimited On-Demand NK and CAR-NK Cells for...